Literature DB >> 29449505

Detection of Crohn Disease in Patients with Spondyloarthropathy: The SpACE Capsule Study.

Uri Kopylov1,2, Michael Starr1,2, Craig Watts1,2, Serge Dionne1,2, Marc Girardin1,2, Ernest G Seidman3,4.   

Abstract

OBJECTIVE: Inflammatory bowel disease (IBD) is generally reported to be associated with spondylarthropathies (SpA) in 5%-15% of cases. Systematic colonoscopic assessment by protocol demonstrated mucosal inflammation characteristic of Crohn disease (CD) in up to one-third of patients with SpA. Video capsule endoscopy (CE) is a superior diagnostic tool to detect small bowel mucosal disease. Our study compared the accuracy of CE to standard colonoscopy for detection of inflammatory bowel lesions in patients with SpA, and to describe predictors of small bowel inflammation (SBI) in this cohort.
METHODS: Prospective cross-sectional study of adult patients followed for SpA. Patients were evaluated by CE and standard colonoscopy with biopsies. SBI was quantified using the Lewis Score. Additional screening tests included fecal calprotectin (FCP), C-reactive protein (CRP), and a diagnostic panel of serologic, inflammatory and genetic tests (SGI).
RESULTS: There were 64 patients recruited (53% female, mean age 42 ± 13 yrs). Chronic gastrointestinal (GI) symptoms were present in 57%. CE revealed significant SBI in 27/64 (42.2%), compared to 7/64 (10.9%) by standard colonoscopy (p = 0.035). Elevated FCP was associated with small bowel CD (OR 4.5, 95% CI 1.01-19.9; p = 0.042). No correlation was observed with presence of GI symptoms, CRP, or SGI results. Finding CD led to a change in management in 65.2% of cases.
CONCLUSION: CE uncovered SBI consistent with CD in 42.2% of patients with SpA, with a significant incremental yield over colonoscopy of 31%. FCP levels were significantly correlated with CE results, while GI symptoms and SGI results were poor predictors of SBI.

Entities:  

Keywords:  ANKYLOSING SPONDYLITIS; BIOMARKERS; CROHN DISEASE; SPONDYLOARTHRITIS; VIDEO CAPSULE ENDOSCOPY

Year:  2018        PMID: 29449505     DOI: 10.3899/jrheum.161216

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Deep Insight into the Role of MIF in Spondyloarthritis.

Authors:  Brian Wu; Akihiro Nakamura
Journal:  Curr Rheumatol Rep       Date:  2022-07-09       Impact factor: 4.686

Review 2.  Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy.

Authors:  Walter P Maksymowych
Journal:  Front Immunol       Date:  2019-03-07       Impact factor: 7.561

3.  Elevated Serum D-Dimer May Reflect the Presence of Gut Inflammation in Spondyloarthritis.

Authors:  Jiaqi Feng; Jia Li; Yixuan Li; Yuyang Jin; Fang Du; Xiaoxiang Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-21

4.  Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.

Authors:  Jonas Sagard; Tor Olofsson; Elisabeth Mogard; Jan Marsal; Kristofer Andréasson; Mats Geijer; Lars Erik Kristensen; Elisabet Lindqvist; Johan K Wallman
Journal:  Arthritis Res Ther       Date:  2022-02-12       Impact factor: 5.156

Review 5.  Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.

Authors:  Nikoleta Zioga; Dionysios Kogias; Vasiliki Lampropoulou; Nikolaos Kafalis; Charalampos Papagoras
Journal:  Mediterr J Rheumatol       Date:  2022-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.